Company intelligence / Profile preview

Advanced Virology

United States

Ownership: Private
Development stage: Other

Overview

Advanced Virology produces high-fidelity virus stocks and derivative products including wild-type strains, reporter-expressing variants, inactivated virus preparations, and custom mutants. The company aims to eliminate researchers' reliance on poor-quality virus reagents by providing authenticated, validated strains.

Therapeutic areas: OtherInfectious Diseases
Modalities: Virus stock productionReverse genetics systems
Industry: Non-Drug Biotech

Partnerships

Virology Research Services Ltd. (VRS) - strategic partnership combining VRS's testing capabilities with Advanced Virology's engineered virus production

Beyond the preview

Go deeper on Advanced Virology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advanced Virology.

Explore the full profile